期刊文献+

SUZ12蛋白对口腔鳞状细胞癌的致癌作用

Role of SUZ12 in oral squamous cell carcinoma carcinogenesis
下载PDF
导出
摘要 目的分析SUZ12蛋白的表达水平与口腔鳞状细胞癌(OSCC)患者恶性生物学行为的关系,并研究SUZ12蛋白在口腔鳞状细胞癌细胞系中的生物学功能。方法对2008至2013年哈尔滨医科大学附属第一医院96例口腔鳞状细胞癌患者石蜡标本通过免疫组化方法检测SUZ12蛋白的表达;在体外实验中,通过RNA干扰的手段抑制SUZ12蛋白在口腔鳞状细胞癌细胞系中的表达水平。结果 SUZ12蛋白在OSCC组织中表达增高,其增高与肿瘤的分化,淋巴结转移相关(P<0.001);此外,发现抑制SUZ12蛋白的表达抑制了口腔鳞状细胞癌细胞的增殖,促进了口腔鳞状细胞癌细胞的凋亡。结论SUZ12起到癌基因的作用,高表达的SUZ12蛋白水平在口腔鳞状细胞癌发生发展过程中起到重要作用。 Objective To examine a potential correlation of SUZ12 expression with clinicopathological parameters in patients with oral squamous cell carcinoma( OSCC) and investigate the biological function of SUZ12 in OSCC cell line. Methods The SUZ12 expression levels were determined by performing immunohistochemical analysis in 96 patients with OSCC from the First Affiliated Hospital of Harbin Medical University,from 2008 to 2013. In vitro analysis,a stable SUZ12 knocking down cell line was generated with RNAi. Results High SUZ12 expression was found in OSCC tissue and this over-expression was associated with tumor differentiation,lymph node metastasis( P 〈0. 001),furthermore,knocking down of SUZ12 induced apoptosis and decreased the proliferation ability of OSCC cells. Conclusion SUZ12 acts as an oncogene and high SUZ12 expression promotes carcinogenesis in OSCC.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2014年第4期269-273,共5页 Journal of Harbin Medical University
关键词 口腔鳞状细胞癌 SUZ12 表观遗传学 oral squamous cell carcinoma SUZ12 epigenetics
  • 相关文献

参考文献10

  • 1van Zyl A, Bunn BK. Clinical features of oral cancer[J]. SADJ, 2012,67(10) :566-569.
  • 2Mishra R, Das BR. Cyclin D1 expression and its possible regula- tion in chewing tobacco mediated oral squamous cell carcinoma progression[J]. Arch Oral Biol, 2009,54(10) :917-923.
  • 3Murugan AK, Munirajan AK, Tsuchida N. Ras oncogenes in oral cancer: the past 20 years[J]. Oral Oncol, 2012,48(5):383- 392.
  • 4Sarkis SA , Abdullah BH, Abdul Majeed BA, et al. Immunohisto- chemical expression of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma in relation to proliferation, apopto- sis, angiogenesis and lyrnphangiogenesis [ J ]. Head Neck Oncol, 2010,2 : 13.
  • 5Kirmizis A, Bartley SM, Farnham PJ. Identification of the poly- comb group protein SU (Z)12 as a potential molecular target for human cancer therapy[ J]. Mol Cancer Ther, 2003,2 ( 1 ) : 113- 121.
  • 6Pizzatti L, Binato R, Cofre J, et al. SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of ehronie mye- loid leukemia [ J ]. Genes Chromosomes Cancer, 2010,49 ( 2 ) : 107-118.
  • 7Pasini D, Bracken AP, Jensen MR, et al. Suzl2 is essential for mouse development and for EZH2 histone methyltransferase activity [J]. EMBO J, 2004,23(20) :4061-4071.
  • 8Jung JW, Lee S, Seo MS, et al. Histone deacetylase controls a- dult stern cell aging by balancing the expression of polycomb genes and jumonji domain containing 3 [ J]. Cell Mol Life Sci, 2010,67 (7) :1165-1176.
  • 9Turgeon N, Blals M, Delabre JF, et al. The histone H3K27 meth- ylation mark regulates intestinal epithelial cell density-dependent 3roliferation and the inflammatory response [ J ]. J Cell Bioehem, 2013,114 (5) : 1203-1215.
  • 10张丽红,刘杨,李争艳,王正彩.口腔鳞癌及癌前病变组织P16蛋白表达的研究[J].哈尔滨医科大学学报,2008,42(4):370-371. 被引量:3

二级参考文献10

  • 1Rocco JW, Sidransky D. p16 (MTS-1/CDKN2/INK4a) in cancer progression [J]. Exp Cell Res,2001,264( 1 ) :42-55.
  • 2O' Regan EM,Toner ME,Finn SP,et al. p16(INK4A) genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas [ J ]. Hum Pathol, 2008,39 ( 3 ) : 452-458.
  • 3Bardeesy N,Aguirre AJ,Chu GC ,et al. Both p16(Ink4a) and the p19 (Aft)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse[ J]. Proc Natl Acad Sci U S A,2006,103 (15) :5947-5952.
  • 4Honoki K, Stojanovski E, McEvoy M, et al. Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis [ J]. Cancer,2007,110(6) :1351-1360.
  • 5Kinoshita I, Dosaka-Akita H, Mishina T, et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer:potential synergistic effect with altered p53 protein on proliferative activity [ J ]. Cancer Res, 1996,56 (24) :5557-5562.
  • 6Vairaktaris E, Yapijakis C, Psyrri A,et al. Loss of tumour suppressor p16 expression in initial stages of oral oncogenesis [ J ]. Anticancer Res ,2007,27 ( 2 ) :979-984.
  • 7Lin YC, Diccianni MB, Kim Y, et al. Human p16gamma, a novel transcriptional variant of p16 ( INK4A), coexpresses with p16 (INK4A) in cancer cells and inhibits cell-cycle progression [ J]. Oncogene,2007,26 (49) :7017-7027.
  • 8Ball E, Bond J, Franc B, et al. An immunohistochemical study of p16 (INK4a) expression in muhistep thyroid tumourigenesis [ J ]. Eur J Cancer,2007,43 ( 1 ) : 194-201.
  • 9Hunter T,Pines J. Cyclins and cancer Ⅱ :Cyclin D and CDK inhibitor 3 come of age [ J ]. Cell, 1994,79 ( 4 ) : 573-582.
  • 10Marx J. New tumor suppressor may rival P53 [ J]. Science, 1994, 264(5157) :344- 345.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部